Lipid and sterol gene sequence variation in autism and correlates with neurodevelopmental status

A pilot study

Trevor Hall, Robert D. Steiner, Hollis Wright, Beth Wilmot, Jean-Baptiste Roullet, Meaghan Peters, Michael Harris

Research output: Contribution to journalArticle

Abstract

Objective: Research has uncovered potential links between lipid and sterol metabolism and autism spectrum disorder (ASD). We worked to characterize genetic sequence variants in lipid/sterol related genes in children affected with ASD to investigate the association between lipid/sterol gene sequence variation and neurodevelopmental phenotype that could identify new etiologies for ASD and eventually aid to focus intervention strategies. Design and methods: Children with confirmed ASD were recruited from a regional academic health center. Participants included 24 children (20 male and 4 female) between the ages of 40 to 81 months (M=60 months). Several neurodevelopmental measures were administered which provided an assessment of neurodevelopmental functional status. We applied our exome sequencing workflow to perform alignment to the Human Reference Sequence (build 37) base calling for every base pair in the reads that align to the reference sequence QC evaluation of the annotation of all genetic variants different from the reference sequence using dbSNP and the 1000 Genomes databases. We investigated whether novel variants identified were related to neurodevelopmental functioning. Results and conclusions: Variants occurred in 355 total genomic positions, 53 of which were not previously annotated as variant positions in either dbSNP or the 1000 Genomes Project's variant annotation. Of these 355 variants, 169 were nonsynonymous (31 were novel). The total number of variants observed in the exons of captured regions of an individual participant ranged from 88 to 117; novel variants ranged from four to 10 per participant, while nonsynonymous variants ranged from 36 and 51 per participant. The total number of nonsynonymous variants per subject was significantly associated with neurodevelopmental function. Further, several genes involved in sterol and lipid metabolism including NPC1, DHCR24 and others that when mutated cause diseases with ASD characteristics, were associated with ASD in Network analysis. Altogether, the findings suggest that nonsynonymous variants in lipid/sterol related genes may be a biological marker of neurodevelopment status in ASD. Results support an association between lipid and sterol metabolism and ASD and suggest the need for further research attempting to elucidate the mechanisms behind the association and the etiology and neurodevelopmental effects of ASD. Focal points: •BedsideUnderstanding the association between genetics and metabolism and ASD will contribute to the scientific understanding of complex neurodevelopmental disorders. Continued study into the association between lipid and sterol genes and ASD may lead to new novel and effective treatment options for ASD.•BenchsideA large number of genetic sequence variations are associated with ASD. Additional research is still needed to determine which associations contribute to various subtypes of ASD presentations, and to elucidate the mechanisms behind the observed association.•IndustryThe discovery of new genetically influenced ASD subtypes may lead to the development of new novel and effective treatment options for ASD.•CommunityThe development of new novel and effective treatment options for ASD will have a great impact on the quality of life of those impacted by ASD.•Regulatory agenciesSince the development of new novel and effective treatment options for ASD based on genetic substrates of the condition needs extensive support from the authorities for success in clinical translation, ongoing financial investments will be necessary to translate the research in the lab to the bedside. The governmental support can also help to minimize the associated costs of treating ASD overtime.

Original languageEnglish (US)
Pages (from-to)137-146
Number of pages10
JournalNew Horizons in Translational Medicine
Volume2
Issue number6-7
DOIs
StatePublished - Sep 1 2015

Fingerprint

Sterols
Autistic Disorder
Lipids
Genes
Lipid Metabolism
Autism Spectrum Disorder
Research
Genome
Exome
Workflow

Keywords

  • Autism
  • Cholesterol metabolism
  • Genetics
  • Lipid/sterol gene sequence variation
  • Neurodevelopmental phenotype

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lipid and sterol gene sequence variation in autism and correlates with neurodevelopmental status : A pilot study. / Hall, Trevor; Steiner, Robert D.; Wright, Hollis; Wilmot, Beth; Roullet, Jean-Baptiste; Peters, Meaghan; Harris, Michael.

In: New Horizons in Translational Medicine, Vol. 2, No. 6-7, 01.09.2015, p. 137-146.

Research output: Contribution to journalArticle

@article{50527e9eeded4ccf86e073970565c0ae,
title = "Lipid and sterol gene sequence variation in autism and correlates with neurodevelopmental status: A pilot study",
abstract = "Objective: Research has uncovered potential links between lipid and sterol metabolism and autism spectrum disorder (ASD). We worked to characterize genetic sequence variants in lipid/sterol related genes in children affected with ASD to investigate the association between lipid/sterol gene sequence variation and neurodevelopmental phenotype that could identify new etiologies for ASD and eventually aid to focus intervention strategies. Design and methods: Children with confirmed ASD were recruited from a regional academic health center. Participants included 24 children (20 male and 4 female) between the ages of 40 to 81 months (M=60 months). Several neurodevelopmental measures were administered which provided an assessment of neurodevelopmental functional status. We applied our exome sequencing workflow to perform alignment to the Human Reference Sequence (build 37) base calling for every base pair in the reads that align to the reference sequence QC evaluation of the annotation of all genetic variants different from the reference sequence using dbSNP and the 1000 Genomes databases. We investigated whether novel variants identified were related to neurodevelopmental functioning. Results and conclusions: Variants occurred in 355 total genomic positions, 53 of which were not previously annotated as variant positions in either dbSNP or the 1000 Genomes Project's variant annotation. Of these 355 variants, 169 were nonsynonymous (31 were novel). The total number of variants observed in the exons of captured regions of an individual participant ranged from 88 to 117; novel variants ranged from four to 10 per participant, while nonsynonymous variants ranged from 36 and 51 per participant. The total number of nonsynonymous variants per subject was significantly associated with neurodevelopmental function. Further, several genes involved in sterol and lipid metabolism including NPC1, DHCR24 and others that when mutated cause diseases with ASD characteristics, were associated with ASD in Network analysis. Altogether, the findings suggest that nonsynonymous variants in lipid/sterol related genes may be a biological marker of neurodevelopment status in ASD. Results support an association between lipid and sterol metabolism and ASD and suggest the need for further research attempting to elucidate the mechanisms behind the association and the etiology and neurodevelopmental effects of ASD. Focal points: •BedsideUnderstanding the association between genetics and metabolism and ASD will contribute to the scientific understanding of complex neurodevelopmental disorders. Continued study into the association between lipid and sterol genes and ASD may lead to new novel and effective treatment options for ASD.•BenchsideA large number of genetic sequence variations are associated with ASD. Additional research is still needed to determine which associations contribute to various subtypes of ASD presentations, and to elucidate the mechanisms behind the observed association.•IndustryThe discovery of new genetically influenced ASD subtypes may lead to the development of new novel and effective treatment options for ASD.•CommunityThe development of new novel and effective treatment options for ASD will have a great impact on the quality of life of those impacted by ASD.•Regulatory agenciesSince the development of new novel and effective treatment options for ASD based on genetic substrates of the condition needs extensive support from the authorities for success in clinical translation, ongoing financial investments will be necessary to translate the research in the lab to the bedside. The governmental support can also help to minimize the associated costs of treating ASD overtime.",
keywords = "Autism, Cholesterol metabolism, Genetics, Lipid/sterol gene sequence variation, Neurodevelopmental phenotype",
author = "Trevor Hall and Steiner, {Robert D.} and Hollis Wright and Beth Wilmot and Jean-Baptiste Roullet and Meaghan Peters and Michael Harris",
year = "2015",
month = "9",
day = "1",
doi = "10.1016/j.nhtm.2015.09.001",
language = "English (US)",
volume = "2",
pages = "137--146",
journal = "European Journal of Molecular and Clinical Medicine",
issn = "2307-5023",
publisher = "Ubiquity Press Ltd.",
number = "6-7",

}

TY - JOUR

T1 - Lipid and sterol gene sequence variation in autism and correlates with neurodevelopmental status

T2 - A pilot study

AU - Hall, Trevor

AU - Steiner, Robert D.

AU - Wright, Hollis

AU - Wilmot, Beth

AU - Roullet, Jean-Baptiste

AU - Peters, Meaghan

AU - Harris, Michael

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Objective: Research has uncovered potential links between lipid and sterol metabolism and autism spectrum disorder (ASD). We worked to characterize genetic sequence variants in lipid/sterol related genes in children affected with ASD to investigate the association between lipid/sterol gene sequence variation and neurodevelopmental phenotype that could identify new etiologies for ASD and eventually aid to focus intervention strategies. Design and methods: Children with confirmed ASD were recruited from a regional academic health center. Participants included 24 children (20 male and 4 female) between the ages of 40 to 81 months (M=60 months). Several neurodevelopmental measures were administered which provided an assessment of neurodevelopmental functional status. We applied our exome sequencing workflow to perform alignment to the Human Reference Sequence (build 37) base calling for every base pair in the reads that align to the reference sequence QC evaluation of the annotation of all genetic variants different from the reference sequence using dbSNP and the 1000 Genomes databases. We investigated whether novel variants identified were related to neurodevelopmental functioning. Results and conclusions: Variants occurred in 355 total genomic positions, 53 of which were not previously annotated as variant positions in either dbSNP or the 1000 Genomes Project's variant annotation. Of these 355 variants, 169 were nonsynonymous (31 were novel). The total number of variants observed in the exons of captured regions of an individual participant ranged from 88 to 117; novel variants ranged from four to 10 per participant, while nonsynonymous variants ranged from 36 and 51 per participant. The total number of nonsynonymous variants per subject was significantly associated with neurodevelopmental function. Further, several genes involved in sterol and lipid metabolism including NPC1, DHCR24 and others that when mutated cause diseases with ASD characteristics, were associated with ASD in Network analysis. Altogether, the findings suggest that nonsynonymous variants in lipid/sterol related genes may be a biological marker of neurodevelopment status in ASD. Results support an association between lipid and sterol metabolism and ASD and suggest the need for further research attempting to elucidate the mechanisms behind the association and the etiology and neurodevelopmental effects of ASD. Focal points: •BedsideUnderstanding the association between genetics and metabolism and ASD will contribute to the scientific understanding of complex neurodevelopmental disorders. Continued study into the association between lipid and sterol genes and ASD may lead to new novel and effective treatment options for ASD.•BenchsideA large number of genetic sequence variations are associated with ASD. Additional research is still needed to determine which associations contribute to various subtypes of ASD presentations, and to elucidate the mechanisms behind the observed association.•IndustryThe discovery of new genetically influenced ASD subtypes may lead to the development of new novel and effective treatment options for ASD.•CommunityThe development of new novel and effective treatment options for ASD will have a great impact on the quality of life of those impacted by ASD.•Regulatory agenciesSince the development of new novel and effective treatment options for ASD based on genetic substrates of the condition needs extensive support from the authorities for success in clinical translation, ongoing financial investments will be necessary to translate the research in the lab to the bedside. The governmental support can also help to minimize the associated costs of treating ASD overtime.

AB - Objective: Research has uncovered potential links between lipid and sterol metabolism and autism spectrum disorder (ASD). We worked to characterize genetic sequence variants in lipid/sterol related genes in children affected with ASD to investigate the association between lipid/sterol gene sequence variation and neurodevelopmental phenotype that could identify new etiologies for ASD and eventually aid to focus intervention strategies. Design and methods: Children with confirmed ASD were recruited from a regional academic health center. Participants included 24 children (20 male and 4 female) between the ages of 40 to 81 months (M=60 months). Several neurodevelopmental measures were administered which provided an assessment of neurodevelopmental functional status. We applied our exome sequencing workflow to perform alignment to the Human Reference Sequence (build 37) base calling for every base pair in the reads that align to the reference sequence QC evaluation of the annotation of all genetic variants different from the reference sequence using dbSNP and the 1000 Genomes databases. We investigated whether novel variants identified were related to neurodevelopmental functioning. Results and conclusions: Variants occurred in 355 total genomic positions, 53 of which were not previously annotated as variant positions in either dbSNP or the 1000 Genomes Project's variant annotation. Of these 355 variants, 169 were nonsynonymous (31 were novel). The total number of variants observed in the exons of captured regions of an individual participant ranged from 88 to 117; novel variants ranged from four to 10 per participant, while nonsynonymous variants ranged from 36 and 51 per participant. The total number of nonsynonymous variants per subject was significantly associated with neurodevelopmental function. Further, several genes involved in sterol and lipid metabolism including NPC1, DHCR24 and others that when mutated cause diseases with ASD characteristics, were associated with ASD in Network analysis. Altogether, the findings suggest that nonsynonymous variants in lipid/sterol related genes may be a biological marker of neurodevelopment status in ASD. Results support an association between lipid and sterol metabolism and ASD and suggest the need for further research attempting to elucidate the mechanisms behind the association and the etiology and neurodevelopmental effects of ASD. Focal points: •BedsideUnderstanding the association between genetics and metabolism and ASD will contribute to the scientific understanding of complex neurodevelopmental disorders. Continued study into the association between lipid and sterol genes and ASD may lead to new novel and effective treatment options for ASD.•BenchsideA large number of genetic sequence variations are associated with ASD. Additional research is still needed to determine which associations contribute to various subtypes of ASD presentations, and to elucidate the mechanisms behind the observed association.•IndustryThe discovery of new genetically influenced ASD subtypes may lead to the development of new novel and effective treatment options for ASD.•CommunityThe development of new novel and effective treatment options for ASD will have a great impact on the quality of life of those impacted by ASD.•Regulatory agenciesSince the development of new novel and effective treatment options for ASD based on genetic substrates of the condition needs extensive support from the authorities for success in clinical translation, ongoing financial investments will be necessary to translate the research in the lab to the bedside. The governmental support can also help to minimize the associated costs of treating ASD overtime.

KW - Autism

KW - Cholesterol metabolism

KW - Genetics

KW - Lipid/sterol gene sequence variation

KW - Neurodevelopmental phenotype

UR - http://www.scopus.com/inward/record.url?scp=84946040386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946040386&partnerID=8YFLogxK

U2 - 10.1016/j.nhtm.2015.09.001

DO - 10.1016/j.nhtm.2015.09.001

M3 - Article

VL - 2

SP - 137

EP - 146

JO - European Journal of Molecular and Clinical Medicine

JF - European Journal of Molecular and Clinical Medicine

SN - 2307-5023

IS - 6-7

ER -